Ritu Aneja - Search Results

Year	Number of Results
2002	1
2003	2
2004	5
2005	3
2006	10
2007	4
2008	4
2009	6
2010	11
2011	14
2012	7
2013	6
2014	12
2015	15
2016	7
2017	17
2018	9
2019	18
2020	16
2021	13
2022	14
2023	9
2024	4

1

Computational benchmarking of putative KIFC1 inhibitors.

Sharma N, Setiawan D, Hamelberg D, Narayan R, Aneja R. Sharma N, et al. Among authors: aneja r. Med Res Rev. 2023 Mar;43(2):293-318. doi: 10.1002/med.21926. Epub 2022 Sep 14. Med Res Rev. 2023. PMID: 36104980 Review.

2

Editorial: Epigenomic drivers of cancer disparities.

Cavalli LR, Ellsworth RE, Aneja R. Cavalli LR, et al. Among authors: aneja r. Front Oncol. 2024 Apr 4;14:1387049. doi: 10.3389/fonc.2024.1387049. eCollection 2024. Front Oncol. 2024. PMID: 38638857 Free PMC article. No abstract available.

3

Editorial: Non-apoptotic cell death mechanisms and their therapeutic significance.

Lopus M, D'Souza JS, Aneja R. Lopus M, et al. Among authors: aneja r. Front Cell Dev Biol. 2022 Oct 26;10:990285. doi: 10.3389/fcell.2022.990285. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36393843 Free PMC article. No abstract available.

4

50 years on … the discovery of tubulin continues to advance cancer treatment.

Crasta K, Aneja R. Crasta K, et al. Among authors: aneja r. Endocr Relat Cancer. 2017 Sep;24(9):E3-E5. doi: 10.1530/ERC-17-0273. Endocr Relat Cancer. 2017. PMID: 28808042 No abstract available.

5

Quadruple-negative breast cancer: novel implications for a new disease.

Bhattarai S, Saini G, Gogineni K, Aneja R. Bhattarai S, et al. Among authors: aneja r. Breast Cancer Res. 2020 Nov 19;22(1):127. doi: 10.1186/s13058-020-01369-5. Breast Cancer Res. 2020. PMID: 33213491 Free PMC article. Review.

6

Lipidomic landscape in cancer: Actionable insights for membrane-based therapy and diagnoses.

Agarwala PK, Aneja R, Kapoor S. Agarwala PK, et al. Among authors: aneja r. Med Res Rev. 2022 Mar;42(2):983-1018. doi: 10.1002/med.21868. Epub 2021 Oct 31. Med Res Rev. 2022. PMID: 34719798 Review.

7

Spotlighting the hypoxia-centrosome amplification axis.

Mittal K, Aneja R. Mittal K, et al. Among authors: aneja r. Med Res Rev. 2020 Jul;40(4):1508-1513. doi: 10.1002/med.21663. Epub 2020 Feb 10. Med Res Rev. 2020. PMID: 32039498

8

Docetaxel-induced polyploidization may underlie chemoresistance and disease relapse.

Ogden A, Rida PC, Knudsen BS, Kucuk O, Aneja R. Ogden A, et al. Among authors: aneja r. Cancer Lett. 2015 Oct 28;367(2):89-92. doi: 10.1016/j.canlet.2015.06.025. Epub 2015 Jul 13. Cancer Lett. 2015. PMID: 26185000 Free PMC article. Review.

9

PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer.

Garlapati C, Joshi S, Bhattarai S, Krishnamurthy J, Turaga RC, Nguyen T, Li X, Aneja R. Garlapati C, et al. Among authors: aneja r. Cell Death Dis. 2023 Jan 10;14(1):12. doi: 10.1038/s41419-022-05539-5. Cell Death Dis. 2023. PMID: 36627281 Free PMC article.

10

SARS-CoV-2 Infection in Cancer Patients: Effects on Disease Outcomes and Patient Prognosis.

Seth G, Sethi S, Bhattarai S, Saini G, Singh CB, Aneja R. Seth G, et al. Among authors: aneja r. Cancers (Basel). 2020 Nov 5;12(11):3266. doi: 10.3390/cancers12113266. Cancers (Basel). 2020. PMID: 33167313 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

184 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Results by year